![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 5
2017
Schübbe, G.-E.; Knösel, T.; Dürr, H. R.; Angele, M.; Röder, F.; Abdel-Rahman, S.; Alig, A.; Gioia, D. di und Lindner, L.
(2017):
Morphological grade of regression after neoadjuvant chemotherapy with doxorubicin/ifosfamide and regional hyperthermia as predictive marker for survival in patients with high-risk soft tissue sarcoma.
In: Oncology Research and Treatment, Bd. 40: S. 111
2016
Ruessel, J.; Lindner, L.; Reichard, P.; Heissner, K.; Kopp, H.-G.; Kessler, T.; Mayer-Steinacker, R.; Egerer, G.; Crysandt, M.; Kasper, B.; Niederwieser, D.; Kunitz, A.; Eigendorff, E.; Steighardt, J.; Cygon, F.; Meinert, F.; Stein, A. und Schmoll, H.-J
(2016):
Pazopanib vs pazopanib/gemcitabine in refractory soft tissue sarcoma: The AIO-STS-009-trial.
In: Oncology Research and Treatment, Bd. 39: S. 306
Weidenbusch, B.; Richter, G.; Teichert-von Lüttichau, I.; Gall, K.; Alter, M.; Dirksen, U.; Lindner, L.; Mansmann, Ulrich und Burdach, S.
(2016):
Transcriptome Based Individualized Therapy Of Refractory Pediatric Bone and Soft Tissue Sarcomas: Feasibility, Tolerability and Efficacy.
In: Oncology Research and Treatment, Bd. 39: S. 127
Issels, R.; Büclein, V.; Kampmann, E.; Knösel, T.; Nössner, E.; Subklewe, M. und Lindner, L.
(2016):
Dissecting the role of tumor-infiltrating lymphocytes (TIL) in patients with high-risk soft-tissue sarcoma (STS) receiving neo-adjuvant chemotherapy (NAC) with regional hyperthermia (RHT).
In: Annals of Oncology, Bd. 27
Schuebbe, G.-E.; Karopmanni, E.; Aubele, P.; Dieterlei, N.; Abdel-Rahman, S.; Ulrich, M.; Issels, R. D. und Lindner, L.
(2016):
Effect of regional hyperthermia (RHT) in combination with neo-adjuvant chemotherapy for treatment of locally advanced high-risk soft-tissue sarcoma (HR-STS) is not dependent on etoposide.
In: Oncology Research and Treatment, Bd. 39: S. 38